Cancer Drug Reimbursement Based On “Value Threshold” Proposed At IoM Workshop
This article was originally published in The Pink Sheet Daily
Executive Summary
Wharton economist Danzon proposes that private payers establish a “value threshold” for cancer drugs based on an outcomes assessment by an independent agency to determine reimbursement.